A surge in direct-to-consumer marketing and prescribing of weight-loss drugs through telehealth platforms has raised concerns about clinical standards, regulatory oversight, and equity in healthcare access in Australia. Patients and health professionals have highlighted the rapid expansion of single-treatment telehealth services offering medications such as glucagon-like peptide-1 (GLP-1) receptor agonists, which have become popular for obesity treatment.

One patient account, documented over several years, reveals persistent and aggressive text message campaigns promoting weight-loss medications with offers and discounts, often describing rapid body transformations without substantive clinical assessments. Despite initially lacking requirements to verify a patient’s weight or conduct video consultations, some platforms later introduced photo uploads following regulatory scrutiny. However, the marketing practices frequently skirt Australian rules prohibiting direct advertisement of prescription medicines.

The proliferation of these services has been fueled by a high demand for weight-loss drugs amid growing obesity rates; approximately two-thirds of Australian adults are overweight or obese. Yet, access remains deeply unequal. For example, Matt Bright from Geelong, who weighs 280 kilograms and has faced life-threatening complications of obesity, struggles to obtain consistent public subsidisation for GLP-1 treatment. With limited financial resources and reliance on public healthcare, Mr. Bright cannot access these drugs reliably via telehealth or through private prescriptions that require out-of-pocket payment.

Experts warn that the commercial incentives embedded in some telehealth business models may undermine clinical integrity and public health objectives. Physicians working for telehealth providers reportedly prescribe weight-loss drugs in high volumes, potentially exceeding appropriate use guidelines, in part because companies involved both prescribe and supply the medications. Such practices risk breaching professional standards and jeopardising arrangements linked to Pharmaceutical Benefits Scheme (PBS) subsidies, which include patient caps to manage public spending.

Monique Ryan, a pediatric neurologist and federal MP, has criticized the apparent conflicts of interest in these commercial operations. She argues there is a regulatory gap in overseeing telehealth companies that deliver narrowly focused prescription services, calling for the establishment of an independent telehealth regulator to address these challenges. Ryan highlighted that existing bodies like the Australian Health Practitioner Regulation Agency (AHPRA) and the Medical Board lack the resources or mandate to effectively police these rapidly growing commercial models.

In response to concerns about "reckless" prescribing practices, AHPRA has announced closer monitoring of high-volume prescribers within the telehealth sector, particularly involving drugs such as GLP-1 weight-loss medications, erectile dysfunction treatments, and medicinal cannabis. The regulator flagged worries that commercial motives might be driving departures from established medical standards.

Meanwhile, pharmaceutical companies and the government continue negotiations over public subsidisation of weight-loss drugs like Wegovy, which is scheduled for review by the nation’s medicines approval committee in November. Economic modelling from the Australian National University suggests that funding GLP-1 drugs as a primary obesity treatment could be cost-neutral or even generate economic benefits by improving workforce participation and reducing disability claims.

While digital platforms have increased access to obesity-related healthcare for some, the divide between private and public access remains stark. The current landscape reflects broader tensions between commercial gain and equitable, evidence-based medical care in addressing one of the country’s most significant public health challenges.